| Today's Big NewsJul 11, 2023 |
| By Zoey Becker A total of 12 severe adverse events were reported among the 40 patients enrolled in the phase 2 trial, 11 of which ADC says were not related to the treatment. The study was assessing the drug in certain patients with previously untreated diffuse large B-cell lymphoma. |
|
|
|
By James Waldron Novartis may have insisted earlier this year that it hadn’t given up on anti-TIGIT checkpoint inhibitors, but, now, the Swiss Big Pharma seems to have had a change of heart. |
By Conor Hale The recall spans more than 21,000 Megadyne return electrode pads distributed to hospitals and surgery centers over a two-year period. |
By Fraiser Kansteiner Moderna has lodged two new lawsuits at the High Court in Dublin, Ireland, and the Brussels Commercial Court in Belgium, Juve Patent first reported. This adds to a complex web of ongoing mRNA patent litigation. |
|
Thursday, July 20, 2023 | 12pm ET / 9am PT In this webinar, you will learn how to capture all healthcare services accurately using multiple datasets, the methodology to capture non-traditional HCP visits, what to look for in an affiliations dataset to help identify non-traditional HCP visits, and more. Register now.
|
|
By Annalee Armstrong BAKX Therapeutics, a small biotech focused on cellular life and death that boasted a partnership with Ipsen, has dissolved. |
By Andrea Park The next big thing on Tandem Diabetes Care’s technology slate is actually a very small thing. The Mobi insulin pump—its smallest device to date and, it claims, the smallest automated insulin delivery system in the world—has secured an FDA clearance. |
By Fraiser Kansteiner Ivan Cheung, Eisai's American CEO and global Alzheimer's disease officer, will retire at the end of the month. With Cheung headed for the exit, Keisuke Naito—the 34-year-old son of Eisai’s CEO Haruo Naito—has taken up the lead Alzheimer’s mantle, the company said Tuesday. |
By Annalee Armstrong The Fed has paused rate hikes and the major indices are starting to look bullish. Could the summer sun finally be shining on the biotech industry again? |
By Andrea Park Better days may have finally arrived for Better Therapeutics, after the company started this year with a swath of layoffs and sustained losses. |
By Angus Liu U.S. travelers and healthcare providers looking for another—and potentially safer—dengue vaccine will have to keep waiting. After an ominous delay, Takeda has decided to withdraw the FDA application for its dengue vaccine candidate after the agency raised concerns about data collection. |
By Nick Paul Taylor Bristol Myers Squibb has pulled the trigger on two neuroscience options, paying Prothena $55 million for a global license to a clinical-phase Alzheimer’s disease drug candidate and handing Evotec $40 million for rights to certain late-stage discovery programs. |
By Angus Liu,Kevin Dunleavy,Eric Sagonowsky In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss new HIV therapies, plus Humira's new biosimilar, foreign pharmaceutical investments, and the rest of the week's headlines. |
|
|---|
|
|
|
Tuesday, July 25, 2023 1pm ET / 10am PT New methods in scalable compute cloud environments not only accelerate drug discovery in a cost-effective manner, but benefit from reduced deployment time, accelerated GPU speed, and reduced infrastructure costs. Register now to learn more.
|
|
| ResearchThe right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookThis eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBookTake a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| |
|
